Rua Bioscience Confirms First International Order

FOR PUBLIC RELEASE
NZX Limited
Wellington

Wednesday 19 October 2022

Rua Bioscience confirms first international order

Rua Bioscience Limited (NZX: RUA) formally announced today that it has received its first order
via its German distributer Nimbus Health, marking a significant commercial milestone for the
export-focused company.

Managing Director, Anna Stove, says “Receiving this order for dried flower from Nimbus signifies
just how close we are to cementing export revenues and providing German patients with a
sustainable supply of Rua medicines”.

The order is for Rua’s high THC flower, which has been developed through an extensive R&D
programme by Cann Group, Rua’s Australian manufacturing, supply and technical services
partner. In Germany, medicinal dried-cannabis flower is prescribed mainly for pain patients (70%),
and cannabis flowers with a THC content of greater than 20% make up 77% of cannabis flower
prescriptions
1
.

“At its launch, we believe Rua’s flower will be one of the highest THC dried flower medicines on
the market, which will give Rua a significant competitive advantage,” she says.

While Rua looks to global markets, the company remains committed to its connection to Te
Tairāwhiti and to patients across New Zealand having launched its first product in Aotearoa in
April.

“The kaupapa to give back to the community will always be in our DNA and entering global
markets will secure meaningful revenue so we can continue prioritising sustainable economic
development in the Ruatorea and East Coast communities,” says Stove.


ENDS

Nimbus
is a fully licensed pharmaceutical wholesaler and manufacturer from Germany with its
own warehouse facilities and an independent sales force to promote medical cannabis-based
products to pharmacists. Nimbus Health is a wholly-owned step down subsidiary of the global
pharma company Dr. Reddy’s Laboratories Ltd. Learn more at: www.nimbus.health

Cann Group
is an established ethical leader in Australia’s emerging medicinal cannabis industry,
building a world-class business focused on breeding, cultivating, manufacturing and supplying
medicinal cannabis. Cann has established research and cultivation facilities in Melbourne and a
MARKET ANNOUNCEMENT

new state-of-the-art cultivation and manufacturing facility near Mildura, Victoria. Learn more at:
www.canngrouplimited.com | www.satipharm.com

Rua
aims to be a leading producer of cannabinoid derived medicines for both export and local
markets. Rua has been an early mover in the sector and was the first private company in New
Zealand to receive a licence to cultivate cannabis for research purposes. Founded in 2017 in
Ruatorea as a subsidiary of charitable company Hikurangi Enterprises Limited, Rua is
underpinned by a mission and its connection to its local community in Te Tairāwhiti. The
company operates state-of-the-art cultivation and manufacturing facilities from its regional base.
www.ruabio.com.

Citations
1
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2021; 64(3): 368–377


For more information, please visit www.ruabio.com or contact:
Kerry Donovan
Communications Manager
Rua Bioscience
M 021 128 7689
kerry.donovan@ruabio.com